Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nasdaq  >  Biogen Inc.    BIIB

BIOGEN INC.

(BIIB)
  Report
Delayed Quote. Delayed Nasdaq - 01/26 04:00:00 pm
271.67 USD   -1.40%
01/25VERICEL : Appoints Joe Mara Chief Financial Officer
MT
01/24SUN TECHNO OVERSEAS : Gets Approval to Change Name
MT
01/22PRESS RELEASE : BB BIOTECH AG: Vaccines leading -2-
DJ
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
 SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies
Most relevant news about BIOGEN INC.
01/19BIOGEN : Morgan Stanley Adjusts Biogen PT to $352 From $357, Maintains Overweigh..
MT
01/14BIOGEN : Aducanumab data review and Q&A with Alzheimer's Disease International
PU
01/13BIOGEN : to Report Fourth Quarter and Full Year 2020 Financial Results February ..
PU
01/13BIOGEN : A statement about Biogen Political Action Committee
PU
01/12DEADLINE TODAY : The Schall Law Firm Announces the Filing of a Class Action Laws..
PR
01/11BIOGEN : Announces First Patient Treated in RESPOND Study Evaluating Benefit of ..
AQ
01/11BIOGEN : to Participate in Webinar with Alzheimer's disease International on Jan..
AQ
01/11BIOGEN : to Launch Study to Develop Digital Biomarkers of Cognitive Health Using..
MT
01/11BIOGEN : to Launch Pioneering Study to Develop Digital Biomarkers of Cognitive H..
AQ
01/08BIOGEN : to Participate in Webinar with Alzheimer's Disease International on Jan..
PU
01/08THE LAW OFFICES OF FRANK R. CRUZ : Reminds Investors of Looming Deadline in the ..
BU
01/08BIIB INVESTOR ALERT : Bronstein, Gewirtz & Grossman, LLC Reminds Biogen Inc. Sha..
BU
01/08DEADLINE REMINDER : Law Offices of Howard G. Smith Reminds Investors of Looming ..
PR
01/08BIOGEN : Treats First Patient in Study of SPINRAZA to Treat Children With Spinal..
MT
01/08Biogen Announces First Patient Treated in RESPOND Study Evaluating Benefit of..
GL
More most relevant news
All news about BIOGEN INC.
01/25VERICEL : Appoints Joe Mara Chief Financial Officer
MT
01/24SUN TECHNO OVERSEAS : Gets Approval to Change Name
MT
01/22PRESS RELEASE : BB BIOTECH AG: Vaccines leading -2-
DJ
01/19BIOGEN : Morgan Stanley Adjusts Biogen PT to $352 From $357, Maintains Overweigh..
MT
01/14BIOGEN : Aducanumab data review and Q&A with Alzheimer's Disease International
PU
01/13BIOGEN : to Report Fourth Quarter and Full Year 2020 Financial Results February ..
PU
01/13DENALI THERAPEUTICS : Strategic Outlook, Upcoming Data for DNL310 Warrant Price ..
MT
01/13BIOGEN : A statement about Biogen Political Action Committee
PU
01/12DEADLINE TODAY : The Schall Law Firm Announces the Filing of a Class Action Laws..
PR
01/11EISAI : Lilly Alzheimer's drug slows mental, functional decline in mid-stage tri..
RE
More news
News in other languages on BIOGEN INC.
01/22BB Biotech a étoffé ses gains en 2020 et va en faire profiter ses actionnaire..
01/22BB Biotech 2020 mit etwas höherem Gewinn und erneuter Dividendenerhöhung
01/11EISAI : Medicamento de Eli Lilly para el alzhéimer retrasa declive mental y func..
01/02Die Tops und Flops 2020 im Nasdaq 100
2020BIOGEN : accord de collaboration avec Sage Therapeutics
2020Laborgeschäft und Halbleiter geben Merck Schub - Prognose angehoben
2020Laborsparte und Halbleiter geben Merck Schub - Prognose nochmals aufgebessert
2020MERCK IM FOKUS : Der Umbau zahlt sich an der Börse aus
2020Aktien New York Schluss: Biden, Corona-Impfstoff treiben Dow auf Rekord
2020USA : Le titre Biogen chute de 30% après le rejet de son traitement contre Alzhe..
More news
Analyst Recommendations on BIOGEN INC.
01/19BIOGEN : Morgan Stanley Adjusts Biogen PT to $352 From $357, Maintains Overweigh..
MT
2020RBC Capital Adjusts Biogen's Price Target to $256 From $249, Maintains Sector..
MT
2020RBC Capital Adjusts Biogen's Price Target to $249 from $244, Keeps Sector Per..
MT
2020DZ Bank Upgrades Biogen to Buy From Hold; Price Target Adjusted to $265 From ..
MT
2020Biogen Down Over 32%, on Pace for Largest Percent Decrease Since February 200..
DJ
More recommendations
Press releases
01/14BIOGEN : Aducanumab data review and Q&A with Alzheimer's Disease International
PU
01/13BIOGEN : to Report Fourth Quarter and Full Year 2020 Financial Results February ..
PU
01/13BIOGEN : A statement about Biogen Political Action Committee
PU
01/12DEADLINE TODAY : The Schall Law Firm Announces the Filing of a Class Action Laws..
PR
01/11BIOGEN : Announces First Patient Treated in RESPOND Study Evaluating Benefit of ..
AQ
More press releases
Upcoming event on BIOGEN INC.